A drug to treat advanced prostate cancer should be given to patients on the NHS, a health watchdog has said.
Abirateron, marketed as Zytiga, can extend the lives of late-stage cancer sufferers by more than three months.
The National Institute for Health and Clinical Excellence (Nice) revised its recommendations after fresh information from manufacturer Janssen, and the new draft guidance was welcomed by experts.
More top news
Temperatures will feel a little milder compared to of late with highs reaching 14C (57F).
Dozens of common treatments to help with a range of ailments are apparently of little or no use.
The prime minister has offered Scotland, Wales and Northern Ireland a "direct line" to Brexit Secretary David Davis.